PRESS RELEASE

XIFIN to Present at 17th Annual Executive War College on Laboratory and Pathology Management Session Evaluates Opportunities for Investment in Genetic Testing

San Diego, Calif., - April 17, 2012 - XIFIN Inc., the company revolutionizing revenue cycle management for diagnostic service providers, today announced that Rina Wolf, VP of Commercialization Strategies, Consulting and Industry Affairs, has been selected to speak at the 17th annual Executive War College on Laboratory and Pathology Management, May 1-2, 2012 in New Orleans, LA.

The Executive War College is the premier conference of its kind, providing access to more than 80 laboratory and pathology experts presenting sessions on laboratory innovations, strategy and profitability.

Rina Wolf will be presenting the extended program, "Evaluating Opportunities for Investment in Genetic Testing: Turning Good Science into Good Business," on Tuesday, May 1, 2012 from 3:30 PM - 4:15 PM. The session will highlight the best opportunities for new molecular diagnostic tests, barriers to commercialization and reimbursement, and how to ensure commercialization success.

"One big challenge for any laboratory or company developing a molecular or genetic test is to obtain favorable coverage decisions and adequate reimbursement from Medicare and private health insurers," stated Robert L. Michel, Editor-In-Chief of The Dark Report and founder of the Executive War College. "Rina Wolf is one of just a handful of experts in the lab testing industry with a demonstrated track record in successfully launching new molecular and genetic assays. Her presentation will be highly useful for anyone preparing to bring proprietary lab tests to the clinical marketplace, particularly since Rina will not only identify the essential steps that need to be taken, but will also share some of the overlooked pitfalls. Her presentation will be chock-full of practical knowledge."

Rina will also be participating as a panelist in the post-conference workshop, "Getting Paid for Molecular and Genetic Tests: Latest Changes in How Government and Private Payers Want to Reimburse Labs," on Thursday, May 3. The panel will provide insights on the many changes taking place in how government and private payers want to develop coverage guidelines and establish reimbursement for molecular diagnostic assays and genetic tests. Attendees can expect some interesting predictions about future payer revisions to coverage and reimbursement guidelines.

XIFIN delivers SaaS revenue cycle management systems that enable labs to improve cash collections and gain efficiencies that substantially improve profitability. More than 50 percent of the industry's largest labs currently use XIFIN's automated, end-to-end interoperable platform to capture revenue faster and better manage claims processing for maximum productivity and profitability.

XIFIN processes more than 100 million claims per year across a wide variety of healthcare segments including clinical, hospital outreach, anatomic pathology, molecular diagnostics, toxicology, radiology and more. Customers see a 50-100% improvement in profitability by using the XIFIN system, and have realized cumulative gains of $1 billion in net cash collection, adjusted for growth.

For additional information about the Executive War College, or to register, visit http://www.executivewarcollege.com.


About XIFIN

XIFIN is an innovative software and services company dedicated to optimizing the economics of healthcare. The company's cloud-based technology and business intelligence platform links healthcare stakeholders in the delivery and reimbursement of care, optimizing both business and patient outcomes and providing informed, streamlined diagnostic and business decision-making. To learn more, visit www.XIFIN.com, or follow XIFIN on Twitter at www.twitter.com/#!/xifin.


XIFIN

Media Relations

To speak with XIFIN directly, contact Fran DuCharme at 858.436.2939 or complete the form below for assistance.

To speak with our PR firm, contact Julie Sculley at 617.986.5730.